Li X, Lebeaupin C, Kadianaki A, Druelle-Cedano C, Vesper N, Rennert C, Huguet-Pradell J, Gomez Ramos B, Fan C, Piecyk RS, Zizmare L, Ramadori P, Li L, Frick L, Qiu M, Zhang C, Martins Nascentes Melo L, Ranvir VP, Shen P, Hanselmann J, Kosla J, Fernández-Vaquero M, Vucur M, Baskaran P, Bao X, Coleman OI, Tang Y, Cetin M, Chen Z, Jang I, Del Prete S, Rahbari M, Zhang P, Pham TV, Hou Y, Sun A, Gu L, Kim LC, Rothermel U, Heide D, Ali A, Gallage S, Talvard-Balland N, Piqué-Gili M, Gris-Oliver A, Bevilacqua A, Schlicker L, Duffey A, Unger K, Szydlowska M, Hetzer J, Odom DT, Machauer T, Bucci D, Sant P, Lee JH, Rösler J, Meckelmann SW, Schreck J, Murray S, Simon MC, Nahnsen S, Schulze A, Ho PC, Jugold M, Breuhahn K, Mallm JP, Schirmacher P, Roth S, Rahbari N, Tschaharganeh DF, Roessler S, Goeppert B, Bengsch B, Andrieux G, Boerries M, Malek NP, Prinz M, Weber A, Zeiser R, Tamayo P, Bronsert P, Kurowski K, Thimme R, Yuan D, Carretero R, Luedde T, Pinyol R, Hartmann FJ, Karin M, Tasdogan A, Trautwein C, Mall M, Hofmann M, Llovet JM, Haller D, Kaufman RJ, Heikenwälder M. Activated ATF6α is a hepatic tumour driver restricting immunosurveillance. Nature. 2026 Feb 4. doi: 10.1038/s41586-025-10036-8. Epub ahead of print.
Fetsch V, Schwöbel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Köhler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Färber J, Braun LM, Zähringer A, Lübbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kühn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712.
Highlighted by: Chakraverty R. Menin inhibitors: a 2-in-1 defense versus AML immune evasion. Blood (2026) 147 (5): 482–483.
